BriaCell Therapeutics Reports Promising Phase 2 Results for Metastatic Breast Cancer Treatment

BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.

BriaCell Therapeutics announced positive results from its Phase 2 Bria-IMT™ study, demonstrating survival and clinical benefits that meet or exceed those of existing FDA-approved therapies for metastatic breast cancer. The promising data, presented at the 2025 ASCO Annual Meeting, suggest that Bria-IMT™ could become a less toxic therapeutic option for heavily pre-treated patients, potentially supporting future Biologics License Application and commercialization efforts.

The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The company is primarily engaged in the development of treatments for metastatic breast cancer, aiming to address urgent, unmet medical needs in this area.

Average Trading Volume: 16,607

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$26.98M

See more data about BCT stock on TipRanks’ Stock Analysis page.